DAREDare Bioscience, Inc.

Nasdaq darebioscience.com


$ 0.31 $ 0.00 (-0.26 %)    

Friday, 03-May-2024 15:52:47 EDT
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 0.3112
$ 0.31
$ 0.00 x 0
$ 0.00 x 0
$ 0.30 - $ 0.32
$ 0.27 - $ 1.06
333,992
na
27.17M
$ 1.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-28-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-30-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-30-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-12-2020 06-30-2020 10-Q
16 05-14-2020 03-31-2020 10-Q
17 03-27-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-14-2019 06-30-2019 10-Q
20 05-14-2019 03-31-2019 10-Q
21 04-01-2019 12-31-2018 10-K
22 11-13-2018 09-30-2018 10-Q
23 08-13-2018 06-30-2018 10-Q
24 05-14-2018 03-31-2018 10-Q
25 03-28-2018 12-31-2017 10-K
26 11-13-2017 09-30-2017 10-Q
27 08-14-2017 06-30-2017 10-Q
28 05-12-2017 03-31-2017 10-Q
29 03-31-2017 12-31-2016 10-K
30 11-03-2016 09-30-2016 10-Q
31 08-04-2016 06-30-2016 10-Q
32 05-02-2016 03-31-2016 10-Q
33 03-10-2016 12-31-2015 10-K
34 11-16-2015 09-30-2015 10-Q
35 08-06-2015 06-30-2015 10-Q
36 05-06-2015 03-31-2015 10-Q
37 03-19-2015 12-31-2014 10-K
38 11-13-2014 09-30-2014 10-Q
39 08-12-2014 06-30-2014 10-Q
40 05-27-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 dar-bioscience-selected-as-a-member-of-arpa-h-investor-catalyst-hub-spoke-network

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced it was selected as a spoke for ...

 hc-wainwright--co-reiterates-buy-on-dare-bioscience-maintains-6-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Dare Bioscience (NASDAQ:DARE) with a Buy and maintains $6 price target.

Core News & Articles

Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023. XOM...

 brookline-capital-downgrades-dare-bioscience-to-hold

Brookline Capital analyst Kemp Dolliver downgrades Dare Bioscience (NASDAQ:DARE) from Buy to Hold.

 dar-bioscience-announces-publication-in-contraception-of-efficacy-and-safety-findings-from-a-pre-pivotal-postcoital-test-study-of-ovaprene-an-investigational-hormone-free-monthly-intravaginal-contraceptive

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 womenPivotal Phase 3 contraceptive e...

 hc-wainwright--co-reiterates-buy-on-dare-bioscience-maintains-6-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Dare Bioscience (NASDAQ:DARE) with a Buy and maintains $6 price target.

 dare-bioscience-q4-eps-006-beats-010-estimate-sales-181m-beat-179m-estimate

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.1...

 earnings-scheduled-for-march-28-2024

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

 dare-bioscience-earnings-preview
Dare Bioscience Earnings Preview
03/27/2024 14:01:04

Core News & Articles

https://www.washingtonpost.com/politics/2024/03/26/abortion-pill-supreme-court-arguments-mifepristone/The Supreme Court on Tues...

Core News & Articles

https://www.washingtonpost.com/world/2024/03/04/france-abortion-constitution/

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION